We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Safety of Bolus vs Infusion Thrombolytic Therapy—Reply

John Eikelboom, MBBS; Shamir Mehta, MD
JAMA. 2001;285(16):2075. doi:10.1001/jama.285.16.2075.
Text Size: A A A
Published online


In Reply: Dr Graumlich suggests that an absolute excess of 2 intracranial hemorrhages per 1000 patients treated with bolus thrombolytic therapy is not clinically relevant. However, clinical relevance cannot be determined solely on the basis of the numbers of patients treated at a single institution. The total burden of disease in the general community must also be considered.

We estimate that the routine adoption of bolus thrombolytic therapy in place of standard infusion therapy will lead to an excess of approximately 1000 cases of intracranial hemorrhage each year in North America,1,2 more than 500 of which will be fatal.3 On a worldwide basis, this translates into thousands of avoidable cases and premature deaths each year with no benefit on reinfarction, other cardiovascular death, or nonhemorrhagic stroke. Irrespective of the alleged failure of hospital formulary committees in the United States to consider the public health implications of modest differences in efficacy or safety between new and established therapies, clinicians cannot ignore the potential impact of this uncommon but devastating complication on the health of their patients.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.